Medications

Added benefit of lisdexamfetamine is not proven

Lisdexamfetamine dimesylate (trade name: Elvanse) has been approved in Germany since March 2013 as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years and ...

Health

Being underweight increases death risk of CAD women by two-fold

Being underweight increases the death risk of women with coronary artery disease (CAD) by 2-fold, according to research presented at the ESC Congress today by Dr Aziza Azimi from Denmark. The study suggests that underweight ...

Surgery

Tackling a framework for surgical innovation

An international team of investigators co-led by Weill Cornell Medical College is offering a new framework for evidence-based surgery and device research, similar to the kind of risk and benefit analysis used in evidence-based ...

page 8 from 13